JNNP: Cerebrospinal fluid phospholipids: a new demyelination biomarker used in the diagnosis and treatment of CIDP and GBS

Objective: Chronic inflammatory demyelinative polyneural root neuropathy (CIDP) and Glyn-Barre syndrome (GBS) are neuropathic lesions mediated by obtaining immunity and have strong heterogeneity in clinical manifestations, prognosis and therapeutic response.
are rare but treatable, early identification is critical.
authors verify that phospholipids (SM) in a patient's cerebrospinal fluid are a reliable biomarker of chronic inflammatory demyelinative polyneurogen neuropathy (CIDP) and Green-Barre syndrome (GBS).
: The authors collected 184 patients from six Italian referral centers, and the cerebrospinal fluid SM levels were quantitatively analyzed using laboratory optimization and fluorescence analysis.
1 ml of cerebrospinal fluid collected clinically is immediately stored for SM testing at -80 degrees C to maintain the integrity of lipids and proteins.
: Confirmed S in cerebrospinal fluid in patients with typical CIDP (n=35), atypical CIDP (n=18) and acute inflammatory demyelination polyneurologosis (AIDP) (n=12) The M level is higher than that of patients with non-demyelination neuropathy (n-85) (p-lt;0.0001, p-0.0065, and p-lt;0.0001).
in CIDP patients classified by disease stage, the SM of active CIDP patients was higher than that of the control group and stable CIDP (p.lt;0.0001).
, the number of SM in AIDP is also increased compared to axial GBS, which distinguishes between demyelination and shaft mutations.
SM was independent of cerebrospinal fluid levels, patients were classified and diagnosed independently of commonly used cerebrospinal fluid indicators, and showed high specificity to avoid possible misdiagnosis.
: CSF-SM is a biomarker for the diagnosis and staged stage of access to demyelinative neuropathy, which can effectively improve the treatment of GBS and CIDP patients.
Caboivento G, De Michelis C, Carpo M, et al CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBSJournal of Neurology, Neurosurgery and Psysurgery Published Online First: 22 October 2020. doi:10.1136/jnnp-2020-324445MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medical and are not authorized and may not be reproduced by any media, website or individual , the authorization should be reproduced with the note "Source: Metz Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here